Indeed, not every type of gene alteration is equally actionable, as it is exemplified by the different sensitivity of HER2-amplified and HER2-mutated cancers to anti-HER2 agents[36]; in this setting, Bayesian phase 1 and 2 study designs have been proposed to adapt drug doses to patient’s PGx profile[37]. This evidence concerns the gene ERBB2 and cancer.